BioAdaptives is a small, early-stage health and wellness company developing and selling natural supplement products and medical devices for humans and animals. Its product lineup targets cognitive enhancement (MyndMed), stem cell activation (Xcellara), weight loss (Zeranovia), lean muscle preservation (Wynovia), and canine aging (PawPa Regen). All active ingredients are derived from plants, fungi, algae, or cyanobacteria. BioAdaptives also owns the Lung Flute, an FDA-cleared Class II medical device for airway clearance acquired in 2024, which is the only product in the portfolio with an existing commercial history. BioAdaptives does not manufacture anything itself — it sources all ingredients and finished products from third-party suppliers. The company sells primarily direct-to-consumer through its website and social media, and also pursues telehealth partnerships and influencer affiliate marketing as distribution channels. Most of its current product line is still in pre-launch, clinical trial, or reformulation phases, making the company essentially pre-revenue. BioAdaptives has one full-time employee and relies heavily on outside consultants, keeping its cost structure largely variable. The company's near-term focus is completing its product launches beginning in Q2 2025, expanding Lung Flute distribution into medical, pharmacy, and senior care channels, and embedding its supplements within telehealth platforms.